UNICEF & Gilead Sciences

UNICEF: UNICEF has sent initial relief supplies, including disinfectants, protective equipment, and water purification tablets, to Bunia to aid in the Ebola response.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

UNICEF: UNICEF is concerned about the impact of the Ebola outbreak on children, especially given high malnutrition levels and patchy vaccination rates in affected areas, and is dispatching urgent medical supplies.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

UNICEF: UNICEF>>> has mobilized supplies and an Emergency Rapid Response team to provide technical assistance and support for risk communication and community engagement in the affected areas.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

UNICEF: Appealed for additional funding, with only 25% of required resources available.

Gilead Sciences: Developed obeldesivir, the antiviral being tested in the EBO-PEP trial.